Elevance Health, Inc. $ELV Shares Bought by Prana Capital Management LP

Prana Capital Management LP grew its position in Elevance Health, Inc. (NYSE:ELV) by 798.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,633 shares of the company’s stock after acquiring an additional 45,889 shares during the period. Prana Capital Management LP’s holdings in Elevance Health were worth $16,684,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. CIBC Bancorp USA Inc. acquired a new position in Elevance Health during the 3rd quarter worth approximately $10,047,000. Centaurus Financial Inc. raised its stake in shares of Elevance Health by 65.3% during the 3rd quarter. Centaurus Financial Inc. now owns 3,416 shares of the company’s stock worth $1,104,000 after buying an additional 1,349 shares in the last quarter. Tweedy Browne Co LLC acquired a new stake in shares of Elevance Health in the 3rd quarter valued at approximately $871,000. Auxier Asset Management LLC boosted its stake in shares of Elevance Health by 0.9% in the third quarter. Auxier Asset Management LLC now owns 37,096 shares of the company’s stock valued at $11,986,000 after buying an additional 343 shares in the last quarter. Finally, Captrust Financial Advisors boosted its stake in shares of Elevance Health by 0.3% in the third quarter. Captrust Financial Advisors now owns 42,653 shares of the company’s stock valued at $13,782,000 after buying an additional 117 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Stock Up 1.4%

Elevance Health stock opened at $296.14 on Wednesday. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The firm has a market capitalization of $65.36 billion, a price-to-earnings ratio of 11.79, a price-to-earnings-growth ratio of 1.60 and a beta of 0.51. The stock’s fifty day moving average is $335.31 and its two-hundred day moving average is $334.16. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.3%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is 27.39%.

Analysts Set New Price Targets

Several research analysts have issued reports on ELV shares. Wolfe Research set a $425.00 price objective on Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Royal Bank Of Canada lowered shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price on the stock. in a research report on Tuesday, February 3rd. Morgan Stanley lowered their price target on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 17th. JPMorgan Chase & Co. increased their price target on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Finally, Sanford C. Bernstein reduced their price objective on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Twelve investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $387.40.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.